AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AMRX · NASDAQ · Drug Manufacturers - Specialty & Generic

Amneal Pharmaceuticals (AMRX)

Developer and manufacturer of generics, injectables, biosimilars, and branded neurology medicines.

$18.97

vs last close−0.53 (−2.72%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	620	617	659	702	702	731	695	725	785	814	723	796
Cost of revenue	388	392	421	452	433	468	440	438	511	517	402	462
Gross profit	233	225	238	250	270	263	256	286	274	297	320	335
	157	211	249	154	181	187	156	175	274	183	177	189
Research & development	42	47	39	37	61	56	42	50	63	35	38	41
	113	109	113	116	119	129	118	124	138	146	139	149
Selling & marketing	0	12	0	0	0	34	0	0	0	0	0	0
General & administrative	0	97	0	0	0	94	0	0	0	0	0	0
Other expenses	2	56	97	1	1	2	−5	1	73	1	0	−1
Operating income	76	14	−11	95	89	76	100	111	0	115	143	146
	−53	−98	−65	−75	−73	−91	−63	−60	−5	−59	−63	−75
Interest expense	51	60	66	66	66	62	57	65	63	56	53	55
Other non-operating income	2	38	−1	9	8	29	6	−5	−58	3	0	0
Income before tax	23	−83	−76	20	15	−15	37	52	−5	55	80	71
Income tax expense	−2	10	6	4	4	5	13	16	−23	6	2	1
Net income from continuing operations	25	−93	−82	17	12	−21	25	36	18	50	78	70
Net income	10	−99	−92	6	0	−31	12	22	2	35	62	58
EPS, basic	$0.06	−$0.40	−$0.30	$0.02	−$0.00	−$0.10	$0.04	$0.07	$0.01	$0.11	$0.20	$0.18
EPS, diluted	$0.06	−$0.40	−$0.30	$0.02	−$0.00	−$0.10	$0.04	$0.07	$0.01	$0.11	$0.19	$0.18
Weighted average shares, basic	161	244	305	309	310	310	311	314	314	313	316	319
Weighted average shares, diluted	160	244	307	319	310	310	324	322	325	325	329	328
EBITDA	131	33	46	142	140	112	155	177	112	161	186	194
Depreciation & amortization	57	57	56	56	59	66	60	60	54	49	43	48
EBIT	74	−24	−10	86	81	46	94	117	58	111	143	146